Huma's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang, eUday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Ocugen Inc executives and other stock owners filed with the SEC include: